BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Vitamin D receptor (VDR) gene polymorphisms could be considered one of the factors influencing the efficacy of the anti-osteoporotic treatments. In this multicenter, prospective, randomized and controlled trial we evaluated whether BsmI vitamin D receptor (VDR) genotypes influence the efficacy of antiresorptive treatment regimes (administered alone or in combination) in postmenopausal osteoporotic women. Using restriction endonuclease, we identified the BsmI VDR polymorphism in 1,100 postmenopausal women with osteoporosis. The women were randomized, taking account of genotype, into five treatment groups: (1) alendronate (Aln, 10 mg/day) plus raloxifene (Rlx, 60 mg/day); (2) Aln plus hormone replacement therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate); (3) Aln alone; (4) HRT alone; and (5) Rlx alone. Lumbar-spine bone mineral density (BMD) and bone turnover markers were measured at study entry and after 1 year of treatment. Using the general linear model (GLM) repeated-measures procedure, the means of BMD and bone turnover markers significantly differed from baseline after a period of treatment. In particular, the mean change from baseline for BMD was -0.034 (95% confidence interval [CI]: -0.037 to -0.031, P <0.001); for serum osteocalcin (OC) it was 1.369 (95% CI: 1.289 to 1.448, P <0.001); and for urinary deoxypyridinoline (DPD) it was 1.322 (95% CI: 1.242 to 1.401, P <0.001), indicating a considerable variation before and after treatment of these indicators. In all three cases these effects appeared significantly influenced by treatments, genotypes, and the treatments*genotypes interaction term (P <0.001 each, except for the BMD and genotype effect with P =0.02), and not by the investigational centers involved in the study. In conclusion, in postmenopausal osteoporotic women, BsmI VDR genotypes influence the efficacy of antiresorptive drugs particularly when used in combination.
Palomba
Stefano
S
Department of Obstetrics and Gynaecology, University Magna Graecia of Catanzaro, Catanzaro, Italy. stefanopalomba@tin.it
Orio
Francesco
F
Russo
Tiziana
T
Falbo
Angela
A
Tolino
Achille
A
Manguso
Francesco
F
Nunziata
Vincenzo
V
Mastrantonio
Pasquale
P
Lombardi
Gaetano
G
Zullo
Fulvio
F
D000284:Administration, Oral; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects / Q000235:genetics; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001862:Bone Resorption / Q000517:prevention & control*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005838:Genotype; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000235:genetics*; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects; D018167:Receptors, Calcitriol / Q000235:genetics*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); D018167:Receptors, Calcitriol; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D017258:Medroxyprogesterone Acetate; D019386:Alendronate
Endocr Rev. 1999 Dec;20(6):788-804
10605626
N Engl J Med. 1997 Jul 10;337(2):77-82
9211676
Endocrinology. 2000 Aug;141(8):2829-36
10919269
J Clin Endocrinol Metab. 2002 Apr;87(4):1502-8
11932272
Hum Genet. 1998 Nov;103(5):576-85
9860300
Nature. 1994 Jan 20;367(6460):284-7
8161378
Calcif Tissue Int. 1995 Dec;57(6):430-5
8581875
J Clin Endocrinol Metab. 1995 Dec;80(12):3657-61
8530616
J Clin Endocrinol Metab. 1995 Sep;80(9):2800-5
7673427
J Bone Miner Res. 2002 Jan;17(1):1-10
11771654
J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17
12161484
J Clin Endocrinol Metab. 2000 Feb;85(2):720-6
10690882
J Clin Endocrinol Metab. 1999 Sep;84(9):3076-81
10487668
Endocr Rev. 2002 Feb;23(1):16-37
11844743
J Clin Endocrinol Metab. 2002 Mar;87(3):983-4
11889148
Osteoporos Int. 1999;10(4):303-6
10692979
JAMA. 2001 Apr 18;285(15):1996-9
11308437
JAMA. 2000 Mar 8;283(10):1318-21
10714731
Am J Obstet Gynecol. 1999 May;180(5):1115-20
10329864
Lancet. 1995 Feb 18;345(8947):423-4
7853953
Calcif Tissue Int. 1997 May;60(5):430-3
9115160
J Bone Miner Res. 1997 Jul;12(7):1049-57
9200004
Endocr Rev. 1998 Feb;19(1):80-100
9494781
Endocrinology. 1992 May;130(5):2597-601
1315250
Hum Reprod. 2000 Oct;15(10):2087-92
11006178
Drugs. 2001;61(7):999-1039
11434454
Lancet. 2002 Jun 8;359(9322):2018-26
12076571
J Bone Miner Res. 1997 Aug;12(8):1241-5
9258754
J Clin Endocrinol Metab. 1998 Mar;83(3):939-44
9506753
J Bone Miner Res. 1995 Apr;10 (4):518-23
7610921
J Clin Endocrinol Metab. 1990 Apr;70(4):1202-7
2318940
JAMA. 2003 May 21;289(19):2525-33
12759324
Drug Metab Dispos. 2001 Apr;29(4 Pt 2):505-12
11259341
Am J Med. 2002 Mar;112(4):281-9
11893367
J Clin Endocrinol Metab. 2002 Mar;87(3):985-92
11889149
Cancer. 2000 Jun 15;88(12 Suppl):2961-78
10898340
Am J Clin Nutr. 1997 Mar;65(3):798-802
9062532